Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04260217
Recruitment Status : Recruiting
First Posted : February 7, 2020
Last Update Posted : July 12, 2021
Sponsor:
Information provided by (Responsible Party):
Ascentage Pharma Group Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : September 30, 2022